Status:
COMPLETED
Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database
Lead Sponsor:
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Ileus
Eligibility:
All Genders
18+ years
Brief Summary
Alvimopan is the first and currently the only FDA-approved therapy for acceleration of the time to upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surge...
Eligibility Criteria
Inclusion
- ≥ 18 years at discharge
- Medical claim with an ICD-9-CM procedure code for a primary procedure (identified at position 1 or 2 involving large or small segmental bowel resection with primary anastomosis
- Discharged within the study dates
- Surgery at a participating Premier/Care Sciences hospital
Exclusion
- Had a diverting ostomy without a primary anastomosis during the index hospitalization
- Had a trauma diagnosis
- Had bowel resections performed on more than 1 day during index hospitalization (this includes cases where a bowel resection and intestinal anastomosis were performed on different days during the index hospitalization)
- Had an excluded non-bowel resection surgical code (i.e., code for a major non-BR surgical procedure \[eg., nephroureterectomy, total joint replacement\] in position 1 or 2
Key Trial Info
Start Date :
April 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
7050 Patients enrolled
Trial Details
Trial ID
NCT01150760
Start Date
April 1 2010
End Date
August 1 2010
Last Update
August 7 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Premier database
Charlotte, North Carolina, United States, 28208